Fibroblast growth factor 21 (FGF-21), a new endocrine hormone with the regulatory effects on energy homeostasis and metabolism of lipid and glucose, has been known to inhibit the inflammation and cell damage caused by oxidative stress in obesity and insulin-resistant states including NAFLD [13]. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.